Soligenix is enrolling patients in its FLASH2 study, with a formal interim analysis anticipated early in 2026. <li /> SNGX's HyBryte is a ...

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company specializing in the development and commercialization of treatments for rare diseases and unmet medical needs, is making significant ...

Improved DL-PDT Effectiveness: CAL pre-treatment boosted the therapeutic impact of daylight photodynamic therapy (DL-PDT) for ...

Scientists are working to create a new light-activated 'smart' bomb to treat aggressive breast cancer. The new light-sensitive chemicals called cyanine-carborane salts are used in photodynamic therapy ...

A wife and husband professor team at Michigan State University are collaborating with researchers at the University of ...

“Our innovative cyanine-carborane salts offer a targeted option with reduced side effects for patients with aggressive breast ...

A wife and husband professor team at Michigan State University are collaborating with researchers at the University of California, Riverside to create a new light-activated “smart” bomb to treat ...

With the increase in antibiotic resistance worldwide, light-induced phototherapies, including photodynamic and photothermal therapy, have attracted interest due to their unique mode of action.

Bringing the beauty industry its Skintuition® philosophy and a first-of-its-kind photodynamic toner PHOENIX, AZ / ACCESS ...

Soligenix (NASDAQ: SNGX) , a late-stage biopharmaceutical company targeting rare diseases, was spotlighted in a recent Zacks Small-Cap Research repor ...

近日，西北工业大学黄维院士、胡文博教授课题组在抗菌光敏化机制研究方面取得了突破性进展。研究成果以“Zwitterionic Photosensitizer-Assembled Nanocluster Produces Efficient ...

A DNA nanomachine selectively targets skin cancer by detecting microRNA-7, activating phototherapy and releasing chemotherapy ...